Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Refractory Dermatomyositis
NCT03002649Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tofacitinib oral solution in dermatomyositis (DM), sponsored by Johns Hopkins University. Primary endpoint: International Myositis Assessment and Clinical Studies Definition of Improvement at 12 weeks. Started Jan 2017; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT03002649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002649.